
David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Your AI-Trained Oncology Knowledge Connection!


David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

David P. Carbone, MD, PhD, discusses the importance of personalizing immunotherapy for patients with non–small cell lung cancer.

David P. Carbone, MD, PhD, discusses a study evaluating acquired resistance to osimertinib in non–small cell lung cancer.

David P. Carbone, MD, PhD, director of the Thoracic Oncology Center at The Ohio State University Comprehensive Cancer Center–James, provides perspective on the novel coronavirus 2019 (COVID-19).

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, discusses the exploration of immunotherapies as treatments for patients with advanced lung cancer.

David P. Carbone, MD, PhD, from the Ohio State University Comprehensive Cancer Center, describes variations in the accuracy and availability of genetic testing technologies.

Published: May 19th 2020 | Updated:

Published: April 1st 2020 | Updated:

Published: May 5th 2020 | Updated:

Published: May 13th 2020 | Updated:

Published: May 19th 2020 | Updated:

Published: July 25th 2013 | Updated: